Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vonoprazan Fumarate

FDA-approved product (tablet, oral), marketed as Voquezna.

Registered studies
24
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Vonoprazan Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gastroesophageal reflux disease
  • Peptic ulcer

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Proton pump inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vonoprazan Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vonoprazan Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of 14-Day Vonoprazan-Minocycline Dual Therapy for Helicobacter Pylori Eradication

    NCT07757919 · start 2026-09-01

    Registered record
    Registry ID
    NCT07757919
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    Vonoprazan-Amoxicillin Dual Therapy; Vonoprazan-Tetracycline Dual Therapy; Vonoprazan-Minocycline Dual Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2027-12-30
    Enrolment
    492

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    InterventionVonoprazan-Amoxicillin Dual Therapy; Vonoprazan-Tetracycline Dual Therapy; Vonoprazan-Minocycline Dual Therapy
    PhasePhase 4
    Registry statusNot yet recruiting

  • 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori

    NCT07352098 · start 2026-02-01

    Registered record
    Registry ID
    NCT07352098
    Conditions
    Helicobacter
    Interventions
    7-day high-dose vonoprazan-amoxicillin dual therapy group; 14-day vonoprazan-amoxicillin dual therapy group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-02-01
    Completion
    2028-02-01
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter
    Intervention7-day high-dose vonoprazan-amoxicillin dual therapy group; 14-day vonoprazan-amoxicillin dual therapy group
    PhaseNot applicable
    Registry statusNot yet recruiting

  • The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients

    NCT07275632 · start 2025-12-10

    Registered record
    Registry ID
    NCT07275632
    Conditions
    Delayed Graft Function; Kidney Transplantation
    Interventions
    Vonoprazan fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-12-10
    Completion
    2026-12-31
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Graft Function; Kidney Transplantation
    InterventionVonoprazan fumarate
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication

    NCT06901375 · start 2025-05

    Registered record
    Registry ID
    NCT06901375
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan; Amoxicillin; Zuojin Wan
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2025-05
    Completion
    2025-08
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan; Amoxicillin; Zuojin Wan
    PhaseEarly phase 1
    Registry statusUnknown

  • Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding

    NCT06783257 · start 2025-02

    Registered record
    Registry ID
    NCT06783257
    Conditions
    Peptic Ulcer Bleeding
    Interventions
    Vonorasan fumarate injection1; Vonorasan fumarate injection2; Esomeprazole sodium for injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-02
    Completion
    2027-02
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeptic Ulcer Bleeding
    InterventionVonorasan fumarate injection1; Vonorasan fumarate injection2; Esomeprazole sodium for injection
    PhasePhase 2
    Registry statusNot yet recruiting

  • Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication

    NCT06340724 · start 2024-02-15

    Registered record
    Registry ID
    NCT06340724
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan; Amoxicillin; Banxiaxiexin decoction
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-02-15
    Completion
    2025-01-15
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan; Amoxicillin; Banxiaxiexin decoction
    PhasePhase 3
    Registry statusCompleted

  • Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection

    NCT06250634 · start 2024-02-10

    Registered record
    Registry ID
    NCT06250634
    Conditions
    Helicobacter Pylori Infection
    Interventions
    esomeprazole + amoxicillin; esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent; Vonoprazan + amoxicillin; Vonoprazan + amoxicillin + clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-02-10
    Completion
    2024-05-10
    Enrolment
    806

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionesomeprazole + amoxicillin; esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent; Vonoprazan + amoxicillin; Vonoprazan + amoxicillin + clarithromycin
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.

    NCT06642987 · start 2023-10-23

    Registered record
    Registry ID
    NCT06642987
    Conditions
    Gastric Ulcer
    Interventions
    Vonoprazan Test 20mg; Vonoprazan Reference 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-10-23
    Completion
    2024-02-23
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Ulcer
    InterventionVonoprazan Test 20mg; Vonoprazan Reference 20mg
    PhasePhase 1
    Registry statusCompleted

  • Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy

    NCT05749081 · start 2023-05-13

    Registered record
    Registry ID
    NCT05749081
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Lacidophilin tablets in combination with vonorazan dual therapy; Placebo in combination with vonorazan dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-05-13
    Completion
    2024-07
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionLacidophilin tablets in combination with vonorazan dual therapy; Placebo in combination with vonorazan dual therapy
    PhasePhase 4
    Registry statusUnknown

  • Helicobacter Pylori and Vonoprazan Dual Therapy

    NCT05649709 · start 2023-02-13

    Registered record
    Registry ID
    NCT05649709
    Conditions
    Helicobacter Pylori
    Interventions
    L-VA dual therapy; H-VA dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-02-13
    Completion
    2024-01-25
    Enrolment
    504

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori
    InterventionL-VA dual therapy; H-VA dual therapy
    PhasePhase 4
    Registry statusCompleted

  • Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection

    NCT05719831 · start 2023-02-01

    Registered record
    Registry ID
    NCT05719831
    Conditions
    Helicobacter Pylori Eradication Rate
    Interventions
    vonoprazan fumarate + high dose amoxicillin（H-10d）; vonoprazan fumarate + low dose amoxicillin（L-10d); vonoprazan fumarate + amoxicillin（H-14d)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-02-01
    Completion
    2023-09-30
    Enrolment
    516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Eradication Rate
    Interventionvonoprazan fumarate + high dose amoxicillin（H-10d）; vonoprazan fumarate + low dose amoxicillin（L-10d); vonoprazan fumarate + amoxicillin（H-14d)
    PhasePhase 3
    Registry statusCompleted

  • Vonoprazan Hp Dual or Triple Eradication Regimes

    NCT05345210 · start 2022-04-25

    Registered record
    Registry ID
    NCT05345210
    Conditions
    Helicobacter Pylori
    Interventions
    Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14); Vonoprazan Fumarate+Amoxycillin 14days (VA14); Vonoprazan Fumarate+Amoxycillin 7days (VA7); Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14); Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-04-25
    Completion
    2023-03-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori
    InterventionVonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14); Vonoprazan Fumarate+Amoxycillin 14days (VA14); Vonoprazan Fumarate+Amoxycillin 7days (VA7); Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14) +1 more
    PhasePhase 4
    Registry statusUnknown

  • Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication of Helicobacter Pylori -- a Multicenter, Randomized, Parallel Controlled Study

    NCT05196945 · start 2022-03-31

    Registered record
    Registry ID
    NCT05196945
    Conditions
    Helicobacter Pylori Eradication Rate
    Interventions
    vonoprazan fumarate + amoxicillin; Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-03-31
    Completion
    2023-02-28
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Eradication Rate
    Interventionvonoprazan fumarate + amoxicillin; Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate
    PhasePhase 4
    Registry statusUnknown

  • Vonoprazan Efficacy to Prevent Post Variceal Band Ligation Ulcer

    NCT05227833 · start 2022-02-15

    Registered record
    Registry ID
    NCT05227833
    Conditions
    Portal Hypertension; Variceal Hemorrhage; Ulcer Hemorrhage
    Interventions
    Vonoprazan fumarate (Vonaspire); Pantoprazole 40mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-02-15
    Completion
    2022-11-15
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortal Hypertension; Variceal Hemorrhage; Ulcer Hemorrhage
    InterventionVonoprazan fumarate (Vonaspire); Pantoprazole 40mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

    NCT05173493 · start 2021-12-30

    Registered record
    Registry ID
    NCT05173493
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin,Furazolidone; Amoxicillin,Levofloxacin; Tetracycline,Furazolidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-30
    Completion
    2023-02-10
    Enrolment
    670

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin,Furazolidone; Amoxicillin,Levofloxacin; Tetracycline,Furazolidone
    PhaseNot recorded
    Registry statusCompleted